15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering AN2 Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $9.00 to $9.00, so the covering firms are broadly aligned. The average target of $9.00 sits 83% above the current $4.93. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.26 next quarter toward $-0.93 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to AN2 Therapeutics Inc.
As of Jul, 2 of 2 firms rate ANTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ANTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.27 – $-0.24 · 2 analysts · -18% YoY
Next period, 2 analysts expect AN2 Therapeutics Inc to earn $-0.26 a share (range $-0.27 – $-0.24), versus $-0.31 a year earlier. Full-year consensus is $-1.04, growing to $-0.93 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering AN2 Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANTX.
#1
Roy Buchanan
JMP Securities · Rank #109
Buy
$2.00-59.4% to target
Overall win rate
48%
+ Follow
#2
Liisa Bayko
Evercore ISI Group
Sell
$2.00-59.4% to target
Coverage
—
+ Follow
#3
BC
Brad Canino
Guggenheim
Buy
$9.00+82.6% to target
Coverage
—
+ Follow
#4
Joseph Schwartz
Leerink Partners
Buy
$9.00+82.6% to target
Coverage
—
+ Follow
#5
Ritu Baral
TD Cowen
Hold
No targeton ANTX
Coverage
—
+ Follow
ANTX stock forecast FAQ
What is ANTX's average 12-month price target?+
The 2 analysts with a live target average $9.00 for AN2 Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $9.00 low.
Is ANTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ANTX?+
2 analysts have an active rating on AN2 Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ANTX?+
Among analysts who currently cover ANTX, Roy Buchanan of JMP Securities has the strongest overall Quantellect track record (Rank #109). Their current call is Buy with a $2.00 target.
What is AN2 Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.27 – $-0.24) across 2 analysts. Full-year EPS is projected at $-1.04, rising to $-0.93 the following year.
How much revenue is AN2 Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ANTX lately?+
As of Jul, 2 of 2 firms rate ANTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
